← Back to Clinical Trials
Recruiting NCT07163780

NCT07163780 The Effect of the HEP Approach in Infants With Down Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07163780
Status Recruiting
Phase
Sponsor Izgi Miray Demirbag
Condition Down Syndrome (DS)
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2025-09-03
Primary Completion 2025-12-03

Eligibility & Interventions

Sex All sexes
Min Age 4 Months
Max Age 12 Months
Study Type INTERVENTIONAL
Interventions
HEP InterventionTraditional Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 26 participants in total. It began in 2025-09-03 with a primary completion date of 2025-12-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the effect of the HEP (Homeostasis-Enrichment-Plasticity) approach on motor and sensory development in infants with Down syndrome. Thirty-two infants will receive either HEP or traditional therapy over 12 sessions, and outcomes will be measured using standardized developmental tests.

Eligibility Criteria

Inclusion Criteria: * Must be between 4 and 12 months old * Must have been diagnosed with Down Syndrome * Must not be at any neurological risk * Parent must agree to participate regularly in the study process Exclusion Criteria: * History of intraventricular hemorrhage (Grade III or IV) * Major vision or hearing impairment * History of febrile convulsion * Medical conditions (e.g., oxygen dependence) that prevent active participation in the study * Participation in other experimental rehabilitation studies

Contact & Investigator

Central Contact

İzgi Miray Demirbağ, Physiotherapist

✉ izgimiray@hotmail.com

📞 +905516626550

Principal Investigator

Aymen Balıkcı, Dr. Physiotherapist

STUDY DIRECTOR

Frequently Asked Questions

Who can join the NCT07163780 clinical trial?

This trial is open to participants of all sexes, aged 4 Months or older, up to 12 Months, studying Down Syndrome (DS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07163780 currently recruiting?

Yes, NCT07163780 is actively recruiting participants. Contact the research team at izgimiray@hotmail.com for enrollment information.

Where is the NCT07163780 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07163780 clinical trial?

NCT07163780 is sponsored by Izgi Miray Demirbag. The principal investigator is Aymen Balıkcı, Dr. Physiotherapist. The trial plans to enroll 26 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology